IP Library › Granted Patent US 12692313
Granted Patent B2
US 12692313 · App. 18/153,990 · Granted Jul 28, 2026

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

Inventors: Martin Pulé (London, GB); Leila Mekkaoui (London, GB); Persis Amrolia (London, GB); Sara Ghorashian (London, GB); Anne Kramer (London, GB); Gordon Cheung (London, GB)
Assignee: AUTOLUS LIMITED
C07K16/2803A61K40/11A61K40/31A61K40/4211C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K14/70596C07K16/3061C12N5/0636A61K2239/31A61K2239/38A61K2239/48C07K2317/56C07K2317/565C07K2317/567C07K2317/622C07K2317/73C07K2319/03C07K2319/33C07K2319/74C12N2510/00C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692313
App. No.
18/153,990
Granted
Jul 28, 2026
Kind
B2
Abstract

There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

Claims (15)

1 . A chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 10.

2 . A cell that comprises the CAR according to claim 1 .

3 . The cell according to claim 2 that is a hematopoietic stem cell or progenitor cell.

4 . The cell according to claim 2 that is a T cell or a natural killer (NK) cell.

5 . A composition that comprises a plurality of cells according to claim 2 .

6 . The composition according to claim 5 , further comprising a pharmaceutically acceptable carrier.

7 . A composition that comprises a plurality of cells according to claim 3 .

8 . The composition according to claim 7 , further comprising a pharmaceutically acceptable carrier.

9 . A composition that comprises a plurality of cells according to claim 4 .

10 . The composition according to claim 9 , further comprising a pharmaceutically acceptable carrier.

11 . A method for making a cell according to claim 2 , which comprises the step of transducing or transfecting a cell with a vector that comprises a nucleotide sequence that encodes a CAR that comprises the amino acid sequence of SEQ ID NO: 10.

12 . The method according to claim 11 , wherein the cell is a T cell or NK cell.

13 . The method according to claim 11 , wherein the cell is a hematopoietic stem cell or progenitor cell.

14 . A nucleic acid comprising a nucleotide sequence that encodes a chimeric antigen receptor (CAR), said CAR comprising the amino acid sequence of SEQ ID NO: 10.

15 . A vector that comprises the nucleic acid according to claim 14 .